The fringe benefits of the new class of weight loss drugs, which includes the diabetes drug Ozempic, its weight loss sister Wegovy, and their cousins Zepbound and Moujnaro, keep adding up. In a new survey from the investment firm Morgan Stanely, which was shared with CNBC and Quartz, people who used glucagon-like peptide-1 (GLP-1) agonist drugs, […]

Related Keywords

Lorenzo Leggio , Casey Arnold , National Institute Of Drug Abuse , Morgan Stanley , National Geographic , National Institute , Drug Abuse , Weight Loss , Alcohol Consumption , Side Effects ,